The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity

被引:164
作者
Guo, Luxuan
Gandhi, Payal N.
Wang, Wen
Petersen, Robert B.
Wilson-Delfosse, Amy L. [1 ]
Chen, Shu G.
机构
[1] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA
关键词
leucine-rich repeat kinase 2; R1441C; Parkinson's disease; Ras-related small GTP-binding; protein; GTPase; MAPKKK;
D O I
10.1016/j.yexcr.2007.07.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the leading cause of autosomal dominant Parkinson's disease (PD). LRRK2, a member of the ROCO protein family, contains both Ras GTPase-like (Roc) and kinase (MAPKKK) domains, as well as other functional motifs. Here, we have identified LRRK2 as the first mammalian ROCO protein that is an authentic and functional GTPase, defined by the ability to bind GTP and undergo intrinsic GTP hydrolysis. Furthermore, the Roc domain is sufficient for this native GTPase activity and binds and hydrolyzes GTP indistinguishably from the Ras-related small GTPase, Rac1. The PD-associated mutation, R1441C, located within the Roc domain, leads to an increase in LRRK2 kinase activity and a decrease in the rate of GTP hydrolysis, compared to the wild-type protein, in an in vitro assay. This finding suggests that the R1441C mutation may help stabilize an activated state of LRRK2. Additionally, LRRK2-mediated phosphorylation is stimulated upon binding of non-hydrolyzable GTP analogs, suggesting that LRRK2 is an MAPKKK-activated intramolecularly by its own GTPase. Since GTPases and MAPKKKs are upstream regulators of multiple signal transduction cascades, LRRK2 may play a central role in integrating pathways involved in neuronal cell signaling and the pathogenesis of PD. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:3658 / 3670
页数:13
相关论文
共 40 条
  • [1] Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease
    Berg, D
    Schweitzer, KJ
    Leitner, P
    Zimprich, A
    Lichtner, P
    Belcredi, P
    Brüssel, T
    Schulte, C
    Maass, S
    Nägele, T
    Wszolek, ZK
    Gasser, T
    [J]. BRAIN, 2005, 128 : 3000 - 3011
  • [2] Localization of LRRK2 to membranous and vesicular structures in mammalian brain
    Biskup, Saskia
    Moore, Darren J.
    Celsi, Fulvio
    Higashi, Shinji
    West, Andrew B.
    Andrabi, Shaida A.
    Kurkinen, Kaisa
    Yu, Seong-Woon
    Savitt, Joseph M.
    Waldvogel, Henry J.
    Faull, Richard L. M.
    Emson, Piers C.
    Torp, Reldun
    Ottersen, Ole P.
    Dawson, Ted M.
    Dawson, Valina L.
    [J]. ANNALS OF NEUROLOGY, 2006, 60 (05) : 557 - 569
  • [3] Roc, a Ras/GTPase domain in complex proteins
    Bosgraaf, L
    Van Haastert, PJM
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2003, 1643 (1-3): : 5 - 10
  • [4] Genetics of Parkinson's disease: LRRK2 on the rise
    Brice, A
    [J]. BRAIN, 2005, 128 : 2760 - 2762
  • [5] Mechanisms of regulating the Raf kinase family
    Chong, H
    Vikis, HG
    Guan, KL
    [J]. CELLULAR SIGNALLING, 2003, 15 (05) : 463 - 469
  • [6] The biochemistry of Parkinson's disease
    Cookson, MR
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2005, 74 : 29 - 52
  • [7] Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease
    Di Fonzo, A
    Tassorelli, C
    De Mari, M
    Chien, HF
    Ferreira, J
    Rohé, CF
    Riboldazzi, G
    Antonini, A
    Albani, G
    Mauro, A
    Marconi, R
    Abbruzzese, G
    Lopiano, L
    Fincati, E
    Guidi, M
    Marini, P
    Stocchi, F
    Onofrj, M
    Toni, V
    Tinazzi, M
    Fabbrini, G
    Lamberti, P
    Vanacore, N
    Meco, G
    Leitner, P
    Uitti, RJ
    Wszolek, ZK
    Gasser, T
    Simons, EJ
    Breedveld, GJ
    Goldwurm, S
    Pezzoli, G
    Sampaio, C
    Barbosa, E
    Martignoni, E
    Oostra, BA
    Bonifati, V
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2006, 14 (03) : 322 - 331
  • [8] LRRK2 mutations in Parkinson disease
    Farrer, M
    Stone, J
    Mata, IF
    Lincoln, S
    Kachergus, J
    Hulihan, M
    Strain, KJ
    Maraganore, DM
    [J]. NEUROLOGY, 2005, 65 (05) : 738 - 740
  • [9] RhoGDI-binding-defective mutant of Cdc42Hs targets to membranes and activates filopodia formation but does not cycle with the cytosol of mammalian cells
    Gibson, RM
    Wilson-Delfosse, AL
    [J]. BIOCHEMICAL JOURNAL, 2001, 359 : 285 - 294
  • [10] The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
    Gloeckner, CJ
    Kinkl, N
    Schumacher, A
    Braun, RJ
    O'Neill, E
    Meitinger, T
    Kolch, W
    Prokisch, H
    Ueffing, M
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 (02) : 223 - 232